🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Bahar Artım-Esen

Istanbul University

ORCID: 0000-0002-5659-3955
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile
0.487Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)

Lara D. Veeken(2024)10.1093/rheumatology/keae583
Top 39%
0.487DataRank
Top 39%8 citations

Massimo Radin, Silvia Grazietta Foddai, Alice Barinotti, Danieli Andrade, Maria G. Tektonidou +23 more

Papers

Driven by 4 papers — median percentile 61. Top paper: “ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)”.

ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)

Lara D. Veeken(2024)10.1093/rheumatology/keae583
Top 39%
0.487DataRank
Top 39%8 citations

Massimo Radin, Silvia Grazietta Foddai, Alice Barinotti, Danieli Andrade, Maria G. Tektonidou +23 more

Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study

Laboratory Investigation(2023)10.1016/j.labinv.2023.100147
N/A
0.312DataRank · unranked
7 citations

Rohan Willis, Danieli Andrade, Maria G. Tektonidou, Vittorio Pengo, Guillermo Ruiz‐Irastorza +67 more

Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry

Lara D. Veeken(2023)10.1093/rheumatology/kead292
N/A
0DataRank · unranked
18 citations

Yasaman Ahmadzadeh, Maria G. Tektonidou, Vittorio Pengo, Savino Sciascia, Amaia Ugarte +64 more

Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries

The Lancet Rheumatology(2025)10.1016/s2665-9913(25)00257-7
N/A
0DataRank · unranked
1 citations

Anne Grete Semb, Michelle Petri, Petros P. Sfikakis, Bahar Artım-Esen, Gabriela Hernández‐Molina +21 more